In our coverage of the inaugural meeting of the MEP Action Group for the Medical Use of Psychedelics, we discussed the challenging experience faced by a psilocybin trial participant after the support provided by the study’s protocol came to an end.
On the very same day that the participant’s testimony was delivered in Brussels, Eddie Jacobs et al. published an article in Neuroethics titled, When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research (2023).
We asked Jacobs, a DPhil student working within the University of Oxford’s NEUROSEC team as well as the Wellcome Centre for Ethics and Humanities, a few questions about post-clinical-trial support.
This content is reserved for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account. Explore the Library here.
